Pascale R M, Marras V, Simile M M, Daino L, Pinna G, Bennati S, Carta M, Seddaiu M A, Massarelli G, Feo F
Institutes of General Pathology, University of Sassari, Italy.
Cancer Res. 1992 Sep 15;52(18):4979-86.
Previous work has shown a consistent fall in S-adenosyl-L-methionine (SAM) in the liver of diethylnitrosamine-initiated rats, during the development of preneoplastic lesions, in persistent nodules (PNs), and hepatocellular carcinomas. The injection of SAM into rats causes the reconstitution of the SAM pool, coupled with growth restraint, remodeling, and apoptosis of preneoplastic cells, and inhibits the development of PNs and hepatocellular carcinomas. To evaluate if SAM treatment causes a long-term prevention of preneoplastic and neoplastic liver lesions or merely causes a delay in their development, we evaluated the effect of a relatively short SAM treatment on the development of preneoplastic and neoplastic lesions in a long-term study. Male Wistar rats were subjected to initiation with diethylnitrosamine, followed by selection and then by the administration of phenobarbital for 16 weeks. After selection, the rats were given i.m. injections of a purified SAM preparation (384 mumol/kg/day) for 24 weeks. In SAM-treated rats, a decrease in the incidence of PNs was found 6, 14, and 24-28 months after initiation. At the end of SAM treatment the number of PNs per rat liver, nodule diameter, and labeling and mitotic indices of nodular cells decreased considerably in control rats. Nodule diameter started to increase rapidly again only 8 months after arresting SAM treatment, when complete recovery of DNA synthesis in nodular cells occurred. The majority of nodules present in the liver 6-28 months after initiation belonged to the clear and acidophilic cell types, with lower percentages of mixed cell and basophilic cell types. A decrease in basophilic nodules occurred in SAM-treated rats. Fourteen and 24-28 months after initiation hepatocellular carcinoma incidence was 11 of 12 and 10 of 10 in control rats, respectively, and only 1 of 12 and 3 of 11 in SAM-treated rats. At the 24th-28th month all control rats had tumors identified as 2 poorly differentiated carcinomas, 6 trabecular carcinomas, or 3 adenocarcinomas, while only 2 relatively small trabecular carcinomas and 1 small glandular tumor developed in SAM-treated rats. In 3 of 11 SAM-treated rats, but in none of the control rats, leukemic infiltration of liver occurred 24-28 months after initiation. Leukemic infiltration of the spleen occurred in 5 and 3 control and SAM-treated rats, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
先前的研究表明,在二乙基亚硝胺引发的大鼠肝脏中,在癌前病变发展过程中、持续性结节(PNs)以及肝细胞癌中,S-腺苷-L-甲硫氨酸(SAM)含量持续下降。给大鼠注射SAM可使SAM池得到重建,同时抑制癌前细胞的生长、重塑和凋亡,并抑制PNs和肝细胞癌的发展。为了评估SAM治疗是能长期预防癌前和肿瘤性肝脏病变,还是仅仅延迟其发展,我们在一项长期研究中评估了相对短期的SAM治疗对癌前和肿瘤性病变发展的影响。雄性Wistar大鼠先用二乙基亚硝胺启动,然后进行筛选,接着给予苯巴比妥16周。筛选后,大鼠肌肉注射纯化的SAM制剂(384 μmol/kg/天),持续24周。在接受SAM治疗的大鼠中,启动后6、14以及24 - 28个月时,PNs的发生率有所降低。在SAM治疗结束时,对照大鼠肝脏中每只大鼠的PNs数量、结节直径以及结节细胞的标记和有丝分裂指数均显著下降。仅在停止SAM治疗8个月后,结节直径才再次开始迅速增加,此时结节细胞中的DNA合成完全恢复。启动后6 - 28个月肝脏中出现的大多数结节属于清亮细胞型和嗜酸性细胞型,混合细胞型和嗜碱性细胞型的比例较低。接受SAM治疗的大鼠中嗜碱性结节减少。启动后14以及24 - 28个月时,对照大鼠肝细胞癌的发生率分别为12只中有11只、10只中有10只,而接受SAM治疗的大鼠中分别为12只中有1只、11只中有3只。在第24 - 28个月时,所有对照大鼠均有肿瘤,分别为2例低分化癌、6例小梁癌或3例腺癌,而接受SAM治疗的大鼠仅发生2例相对较小的小梁癌和1例小腺管肿瘤。在11只接受SAM治疗的大鼠中有3只在启动后24 - 28个月出现肝脏白血病浸润,而对照大鼠中无一例出现。对照大鼠和接受SAM治疗的大鼠中分别有5只和3只出现脾脏白血病浸润。(摘要截断于400字)